These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19139982)

  • 41. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis.
    Hilgard P; Kahraman A; Lehmann N; Seltmann C; Beckebaum S; Ross RS; Baba HA; Malago M; Broelsch CE; Gerken G
    World J Gastroenterol; 2006 Feb; 12(5):697-702. PubMed ID: 16521181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
    Lee JT; Whitson BA; Kelly RF; D'Cunha J; Dunitz JM; Hertz MI; Shumway SJ
    J Surg Res; 2013 Sep; 184(1):599-604. PubMed ID: 23566442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Late-onset acute rejection after living donor liver transplantation.
    Akamatsu N; Sugawara Y; Tamura S; Keneko J; Matsui Y; Hasegawa K; Makuuchi M
    World J Gastroenterol; 2006 Nov; 12(41):6674-7. PubMed ID: 17075982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation.
    Borda B; Lengyel C; Várkonyi T; Kemény E; Ottlakán A; Kubik A; Keresztes C; Lázár G
    Acta Physiol Hung; 2014 Sep; 101(3):388-94. PubMed ID: 25183511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possible therapeutic effect of lipid supplementation on neurological complications in liver transplant recipients.
    Ide K; Ohdan H; Tahara H; Ishiyama K; Shishida M; Irei T; Ohira M; Tashiro H; Itamoto T; Asahara T
    Transpl Int; 2007 Jul; 20(7):632-5. PubMed ID: 17442068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes after liver transplantation: keep the end in mind.
    Bucuvalas JC; Campbell KM; Cole CR; Guthery SL
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S41-8. PubMed ID: 16819401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.
    D'Avola D; Cuervas-Mons V; Martí J; Ortiz de Urbina J; Lladó L; Jimenez C; Otero E; Suarez F; Rodrigo JM; Gómez MA; Fraga E; Lopez P; Serrano MT; Rios A; Fábrega E; Herrero JI
    Liver Transpl; 2017 Apr; 23(4):498-509. PubMed ID: 28160394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
    Gonwa TA; Mai ML; Melton LB; Hays SR; Goldstein RM; Levy MF; Klintmalm GB
    Transplantation; 2001 Dec; 72(12):1934-9. PubMed ID: 11773892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrent reversible cerebral edema after long term immunosuppression with tacrolimus.
    Reinohs M; Straube T; Baum P; Berrouschot J; Wagner A
    J Neurol; 2002 Jun; 249(6):780-1. PubMed ID: 12173578
    [No Abstract]   [Full Text] [Related]  

  • 52. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcineurin inhibitors in heart transplantation.
    Keogh A
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
    Forgacs B; Merhav HJ; Lappin J; Mieles L
    Transplant Proc; 2005 May; 37(4):1912-4. PubMed ID: 15919502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive risk assessment for early neurologic complications after liver transplantation.
    Wu SY; Chen TW; Feng AC; Fan HL; Hsieh CB; Chung KP
    World J Gastroenterol; 2016 Jun; 22(24):5548-57. PubMed ID: 27350733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both?
    Therapondos G; Plevris JN; Dollinger MM; Hayes PC; Flapan AD
    Transplantation; 2003 Jul; 76(2):446-7; author reply 447-8. PubMed ID: 12883220
    [No Abstract]   [Full Text] [Related]  

  • 59. [Calcineurin inhibitors and mechanisms that are responsible for the appearance of post-transplant diabetes mellitus].
    Ippoliti GB; Viganò M
    G Ital Nefrol; 2003; 20 Suppl 25():S11-4. PubMed ID: 14523907
    [TBL] [Abstract][Full Text] [Related]  

  • 60.  Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key.
    Norero B; Serrano CA; Sanchez-Fueyo A; Duarte I; Torres J; Ocquetau M; Barrera F; Arrese M; Soza A; Benítez C
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):94-106. PubMed ID: 28051798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.